M1 Kliniken AGMKLNF 92 ROE % is 17.80% as of Dec. 2025, which is 34% above its 10-year median of 13.26. GuruFocus rates MKLNF with a GF Score™ of 92/100 and a GF Value™ of $10.46. The stock has 3 warning signs investors should review. Among 115 Medical Distribution companies, M1 Kliniken AG ranks better than 84.35% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. M1 Kliniken AG's annualized net income for the quarter that ended in Dec. 2025 was $24.6 Mil. M1 Kliniken AG's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was $138.3 Mil. Therefore, M1 Kliniken AG's annualized ROE % for the quarter that ended in Dec. 2025 was 17.80%.
The historical rank and industry rank for M1 Kliniken AG's ROE % or its related term are showing as below:
MKLNF'
s ROE % Range Over the Past 10 Years
Min: 4.53 Med: 13.26 Max: 19.58
Current: 19.3
During the past 12 years, M1 Kliniken AG's highest ROE % was 19.58%. The lowest was 4.53%. And the median was 13.26%.
MKLNF's ROE % is ranked better than 84.35% of 115
companies
in the Medical Distribution industry
Industry Median: 7.1
vs MKLNF: 19.30
M1 Kliniken AG (OTCPK:MKLNF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
M1 Kliniken AG ROE % Related Terms
M1 Kliniken AG ROE % Historical Data
* Premium members only.
The historical data trend for M1 Kliniken AG's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, M1 Kliniken AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
M1 Kliniken AG ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, M1 Kliniken AG's ROE % distribution charts can be found below:
* The bar in red indicates where M1 Kliniken AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
M1 Kliniken AG (MKLNF) has a ROE % of 17.80% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on M1 Kliniken AG and its competitors. This is 34% above median its historical median of 13.26. Over the past decade, M1 Kliniken AG's ROE % has ranged from 4.53 to 19.58. According to the industry distribution chart, M1 Kliniken AG ranks #18 out of 115 companies in the Medical Distribution industry, placing it in the top 15.7%.
Is M1 Kliniken AG's ROE % too high?
M1 Kliniken AG's current ROE % of 17.80% is 34% above median its 10-year median of 13.26. Over the past 10 years, this metric has ranged from a low of 4.53 to a high of 19.58. The Medical Distribution industry median ROE % is 7.10. M1 Kliniken AG's value of 17.80% is 150.7% above this industry median. Based on the distribution chart, M1 Kliniken AG ranks #18 out of 115 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, M1 Kliniken AG has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does M1 Kliniken AG's ROE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, M1 Kliniken AG ranks #18 out of 115 companies for ROE %. This places M1 Kliniken AG in the top 16% of its industry — outperforming the majority of peers. The industry median ROE % is 7.10. M1 Kliniken AG's value of 17.80% is 150.7% above this benchmark. Historically, M1 Kliniken AG's own ROE % has ranged from 4.53 to 19.58 over the past decade. While the company's 10-year median is 13.26 vs. the industry median of 7.10, M1 Kliniken AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. M1 Kliniken AG's current ROE % of 17.80% is 150.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on M1 Kliniken AG and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. M1 Kliniken AG's current ROE % is 17.80%, which is 34% above median its own 10-year median of 13.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is M1 Kliniken AG stock overvalued right now?
M1 Kliniken AG (MKLNF) has a current ROE % of 17.80%. The stock's GF Value™ is $10.46, compared to a current price of $11.73 — trading 12.1% above its estimated fair value. The current ROE % is 17.80%, which is 34% above median its 10-year median of 13.26 and 150.7% above the Medical Distribution industry median of 7.10. M1 Kliniken AG's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For M1 Kliniken AG (MKLNF), the current ROE % is 17.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is M1 Kliniken AG (MKLNF) Overvalued in 2026?
Based on GuruFocus' analysis, M1 Kliniken AG stock appears to be overvalued.
The current stock price of $11.73 is trading 12.1% above its estimated GF Value™ of $10.46.
Key valuation signals for MKLNF:
ROE %: 17.80% (34% above median its 10-year median of 13.26)
GF Value™: $10.46 vs. price of $11.73 (12.1% above fair value)
Industry Position: 150.7% above the Medical Distribution median (#18 of 115)
No single metric tells the full story. See the MKLNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
M1 Kliniken AG operates in the growing market of aesthetic medicine and plastic surgery and provides aesthetic medical treatments in the self-pay segment. It operates through Beauty and Trade segments. Its activities are focused on providing aesthetic medical treatment. In addition to medical aesthetic treatments, the company also develops and markets pharmaceutical, medical, and medical technology products for aesthetic surgery and cosmetic dermatology. Some of the treatments offered by the group are lip under injection, eyebrow lift, tummy tuck, breast reduction, sweat treatment, liposuction, and others. The organization conducts its business operations in Germany. The majority of its revenue is derived from the Trade segment.
92GF Score
Get the complete analysis for MKLNF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MKLNF has been successfully added to your 
